Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Intelsius Enhances Patient Safety Products

Published: Thursday, February 13, 2014
Last Updated: Wednesday, February 12, 2014
Bookmark and Share
Company announces enhancement to ThermoTrek™ range of solutions.

Intelsius has announced an enhancement to its ThermoTrek™ range of solutions. They now feature ThermoCline Technology™ (TCT) allowing 48 plus hours of protection for temperature sensitive payloads. The TCT addition allows for simple conditioning of a single component making it easy for patients to use correctly.

ThermoTrek systems are a range of insulated, patient carry cases designed for movement of temperature sensitive medications (2-8 degrees C) either being tested in clinical trials or for approved and marketed medicines used by patients.

“Pharmaceutical companies make enormous investments in their IMPs during clinical trials and the ThermoTrek TCT systems will help patients comply with temperature sensitivity requirements and provide more reliable clinical data outcomes,” said Steve Healy, Intelsius Global Sales Director.

In commercially available temperature sensitive medicines, the system protects the patient’s investment in treatment while ensuring efficacy of the medicine.

The optional Thermochromic label on the TCT panel visually indicates and verifies the readiness for use.

“Keeping patients safe is the primary reason for the ThermoTrek TCT line of products and simplified conditioning makes it extremely easy for them to use,” said Healy. “In addition, we’ve already had great feedback from leading Pharma companies who are shipping high value biologics direct to pharmacies here in Europe.”

Every ThermoTrek TCT solution is constructed with high performance materials which give a strong resistance to tears or abrasions while offering stain and water resistance for many months of reliable use.

Each case is ergonomically designed to have a minimum impact on the patient’s daily life and enable comfortable transportation of medicine. In addition, its discreet design keeps the contents confidential.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!